Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

should be classified as a reduction of equity and, accordingly, did not record any reserve charges during the first quarter of 2009. These decreases were partially offset by a $0.1 million increase in professional fees associated with the preparation of the Company's SEC filings.

The Company recorded net interest and other expense of $1.2 million for the first quarter of 2009 compared to net interest and other income of $0.1 million for the first quarter of 2008. The decrease in net interest and other income resulted from an additional impairment in the amount of $0.9 million to the Company's auction rate securities due primarily to their continued illiquidity and a $0.4 million decrease in interest income, due to a decrease in cash and short-term investments during the quarter.

As a result, the Company's net loss for the quarter ended March 31, 2009 was $8.3 million compared to a net loss of $7.8 million for the quarter ended March 31, 2009. The loss for the quarter ended March 31, 2008 includes a loss from discontinued operations of $0.7 million.

As of March 31, 2009, the Company had $25.6 million in cash and investments (including auction rate securities recorded at their fair value) compared to $33.9 million as of December 31, 2008. The decrease of $8.3 million was due to cash spent during the first quarter of $7.4 million and an impairment to the auction rate securities of $0.9 million discussed above. Cash and short-term investments as of March 31, 2009 are net of $2.1 million in cumulative impairment charges recorded for the company's auction rate securities. Based on the amount of cash and short-term investments on hand, the $11.0 million received from the sale of common stock to Cadila on April 1, 2009, the approximately $7.5 million received from sales of common stock under the Wm Smith & Co. sales agreement through May 5, 2009, along with the Company's intention to pay 50% of the balance of its
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Peter Walter ... Biomedical Science for his pioneering work on how proteins ... components of a regulatory mechanism that cells use to ... Dr. Walter is a professor of biochemistry at the ... groundwork for treating a range of human diseases related ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Market ... formed a strategic alliance with Designing Gig LLC to ... clients. , “Forging this alliance with Designing ... Now we can extend a comprehensive, end-to-end, digital solution ... strategy, and execution,” said Chuck Miller, president of The ...
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... N.Y., Sept. 21 According to Dr. Ila R. Singh, an associate ... we have analyzed prostate cancer and normal prostate tissue and found cancers ... also more likely to be present in more aggressive tumors," Singh said. ... over 45 percent of the most aggressive tumors." , , ...
... Ohio, September 21 Simbionix USA Corporation,the world,s leading ... a new Laparoscopic Essential Tasks Module for its LAP,Mentor(TM) ... patient data - the PROcedure Rehearsal Studio(TM). , ... is an addition to the LAP,Mentor,s ever-expanding library of ...
... , LONDON and SAN CARLOS, ... announced today that they have entered into an exclusive worldwide ... stage investigational product being evaluated for the treatment of opioid-induced ... is intended to deliver products for the treatment of pain ...
Cached Biology Technology:As Predicted: Chronic Virus Found Living in Tumors of the Prostate 2Simbionix USA Corporation's Innovative Development Division Releases Two New Breakthrough Technologies 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 3AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 4AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 5
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... Convergence ThemeWASHINGTON, April 8 Supply Chain Council (SCC) ... , the following events around the internationally used standard, ... - 11-12 May 2009 , SCOR Seminar - 13-14 ... 2009Successful use of SCOR with other frameworks and methodologies ...
... April 20, 2009 Concordia University is pleased to ... the Centre for Structural and Functional Genomics have been ... innovative genome research being conducted at Concordia. This ... in Bioproducts or Crops (ABC) competition launched last year ...
... (WASHINGTON, April 20, 2009) - In a recent study, ... into cells that are molecularly and functionally indistinguishable from ... readily accessible source of stem cells and an alternative ... online in Blood , the official journal of ...
Cached Biology News:Supply Chain Council Seminar Focuses on Defense and IT 2Study finds blood cells can be reprogrammed to act as embryonic stem cells 2
... Translation System is ideal for both radioactive ... Translation System: Provides five pre-mixed nucleotide ... Yields >10 8 cpm/g control ... to monitor the performance of the system ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... C-1-tetrahydrofolate synthase, cytoplasmic ... Methylenetetrahydrofolate dehydrogenase (EC ... (EC 3.5.4.9); Formyltetrahydrofolate ... [Source:Uniprot/SWISSPROT;Acc:P11586] ...
Biology Products: